🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS

RecruitingNAAges 18 Years - anyAllFirst Affiliated Hospital of Wannan Medical Colle…
NCT06143488 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patients with minor stroke is a well-established predictor of poor outcomes, while the poor outcomes following best medical management in patients with minor stroke with the underlying presence of a LVO are mainly driven by the occurrence of early neurological deterioration (END). Considering the well-known strong association between lack of arterial recanalization and END, endovascular therapy (EVT) appears as an attractive option to improve functional outcomes for LVO-related patients with stroke with mild symptoms. Whether EVT is safe and effective in patients with mild stroke with an LVO is currently debated, since

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
1. Aged 18 years or older; 2. The time from onset of acute ischemic stroke to randomization is within 24 hours. Onset time is defined as the patient's Last Known Well (LKW); 3. Low NIHSS score (2-5 points), with at least one of the following items: 1. Altered mental status (lethargy or worse); 2. Facial palsy (facial weakness score ≥ 1 point); 3. Motor dysfunction (limb weakness score ≥ 1 point); 4. Aphasia (language disturbance score ≥ 1 point); 5. Hemispatial neglect (neglect score ≥ 1 point); 4. Intracranial internal carotid artery, proximal M1 or M2 segment of middle cerebral artery occlusion confirmed by cerebral CTA/MRA/DSA before randomization, which is identified as the culprit vessel for stroke; 5. All patients receive CTP/MR perfusion imaging, with a volume of perfusion delay (Tmax\>6 s) ≥ 50 mL; 6. Written informed consent is obtained from the patient or legal surrogate, with agreement for long-term follow-up.
💊

What it tests

  • Endovascular therapy
  • Best medical management
📍

Where

1 site
The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College
Wuhu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy